ImmuCell Corporation (NASDAQ:ICCC) Short Interest Update

ImmuCell Corporation (NASDAQ:ICCC) saw a significant increase in short interest during the month of February. As of February 13th, there was short interest totaling 18,071 shares, an increase of 44.1% from the January 29th total of 12,544 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily volume of 17,639 shares, the short-interest ratio is presently 1.0 days. Based on an average daily volume of 17,639 shares, the short-interest ratio is presently 1.0 days. Currently, 0.2% of the company’s shares are sold short.

ImmuCell Trading Down 3.7%

Shares of ICCC stock traded down $0.24 on Tuesday, hitting $6.30. 16,139 shares of the company’s stock traded hands, compared to its average volume of 19,159. The stock has a market capitalization of $57.02 million, a price-to-earnings ratio of 24.23 and a beta of 0.26. The company’s fifty day simple moving average is $6.34 and its 200 day simple moving average is $6.09. ImmuCell has a one year low of $4.28 and a one year high of $7.60. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.76 and a current ratio of 4.21.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of ImmuCell from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 24th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Institutional Investors Weigh In On ImmuCell

Hedge funds and other institutional investors have recently modified their holdings of the stock. Steadtrust LLC bought a new position in ImmuCell during the 3rd quarter worth approximately $198,000. Mesirow Financial Investment Management Inc. lifted its position in ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 24,303 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of ImmuCell by 4.2% during the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 2,907 shares during the period. Institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.